News

Riad Salem, MD, discusses the role of localized therapy in hepatocellular carcinoma, the need to personalize treatment for patients, and the importance of implementing a multidisciplinary approach in this setting.

Trastuzumab emtansine has been approved in the UK for the adjuvant treatment of patients with HER2-positive early breast cancer.

A supplemental New Drug Application has been submitted to the Japanese Ministry of Health, Labour and Welfare seeking approval of trastuzumab deruxtecan for the treatment of patients with HER2-positive metastatic gastric cancer

Adding the PD-1 inhibitor sintilimab injection to gemcitabine and platinum-based chemotherapy improved progression-free survival as a frontline treatment in squamous non–small cell lung cancer.

Heinz-Josef Lenz, MD, FACP, discusses the next steps for the trial examining the onvansertib combination and sheds light on the possibility of this regimen eventually being used in the frontline setting.

Sonali M. Smith, MD, sheds light on some of the recent advances in follicular lymphoma and mantle cell lymphoma, as well as the challenges that remain overall in non-Hodgkin lymphoma.

The FDA has approved capmatinib for the treatment of patients with non–small cell lung cancer.

Investigators are examining if the addition of apalutamide, abiraterone acetate, and prednisone to standard hormone and radiation therapy will be more effective than standard treatment alone in node-positive prostate cancer.

The FDA has granted an orphan drug designation to MIV-818 for the treatment of patients with hepatocellular carcinoma.

Alain Algazi, MD, discusses the SWOG S1320 trial further, the future of intermittent dosing in melanoma, and future clinical trials in the field.

Paul M. Barr, MD, discusses the findings from a phase 1/2 trial and the evolution toward triplet therapies in chronic lymphocytic leukemia.

The FDA has extended the review period for a biologics license application for lisocabtagene maraleucel for the treatment of adult patients with relapsed/refractory large B-cell lymphoma.

Shannon N. Westin, MD, MPH, FACOG, discusses future directions in endometrial cancer.

VERU-111 demonstrated antitumor activity and durable PSA declines in men with metastatic castration-resistant prostate cancer who are resistant to at least 1 novel androgen-blocking agent.

Ritu Salani, MD, discusses the evolving role of biomarker development and testing in cervical cancer.

A doublet combining umbralisib and ublituximab improved progression-free survival in patients with chronic lymphocytic leukemia.

Manuel Hidalgo Medina, MD, PhD, discusses some of the research he presented at the 2020 ACCR Virtual Annual Meeting and future areas of exciting efforts being made in pancreatic cancer.

Cemiplimab induced clinically meaningful and durable responses in patients with advanced basal cell carcinoma.

FGFR2 fusions are significantly less common in endemic fluke-associated cholangiocarcinoma compared with non–fluke-associated cholangiocarcinoma, demonstrating that distinct etiologies could affect the molecular landscape of cholangiocarcinoma tumors.

Udai Banerji, discusses the rationale for a phase 1 trial, the potential implications of these data, and future studies in development.

The combination of nivolumab and regorafenib demonstrated promising antitumor activity in patients with gastric and colorectal cancer.

R. Wendel Naumann, MD, discusses the FDA approval of niraparib in ovarian cancer and the impact on the current treatment paradigm.

Scott T. Tagawa, MD, MS, FACP, provides background on radionuclide therapy, sheds light on the key findings from the trial, and discusses future directions with 225Ac-J591 in mCRPC.

The FDA has granted an orphan drug designation to HQP1351 for the treatment of patients with chronic myeloid leukemia.

A reduction in patient-reported symptomatic adverse events was observed with intensity-modulated radiotherapy compared with standard radiotherapy in patients with cervical or endometrial cancer, whereas no difference was observed with regard to clinician-reported AEs.